Approximately 65 percent of patients with advanced urothelial cancers could potentially benefit from a drug targeting the historically intractable PPAR gamma.
Research pinpointing the mechanism causing myocarditis in some patients on immune checkpoint inhibitors could lead to biomarker tests to identify those at risk.
The researchers hope to determine whether tens of thousands of variants in RUNX1 and GATA2 increase predisposition to blood cancers.
Precision oncology products Tagrisso, Lynparza, and Imfinzi were revenue leaders for AstraZeneca in the third quarter.
The analysis showed a clear benefit for patients with anogenital cancers who received the vaccine plus a checkpoint inhibitor over those who received only a checkpoint inhibitor.
Drugmakers say automation can expand timely access to CAR T-cell therapies, but there's much more research and testing to be done before it can provide relief to patients.
BMS continues renewal of its pipeline with newly launched Opdualag and CAR T-cell therapies Breyanzi and Abecma.
Novartis is ramping up manufacturing capacity at two US sites in anticipation of Pluvicto approvals in early lines of therapy for metastatic prostate cancer.
The new company will advance Ayala's gamma secretase inhibitors and Advaxis' prostate cancer candidate ADXS-504, but lung cancer drug ADXS-503 will be discontinued.
Among NHL patients who received off-label therapy with combinations generated by the platform, nearly half achieved partial or complete responses.